Prostate Active Surveillance Study

Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed) adenocarcinoma of the prostate from a prostate biopsy. - Clinically localized prostate cancer: T1-2, NX or N0, MX or M0. - No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy). - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1. - Patient has elected Active Surveillance as preferred management plan for prostate cancer. - Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens. - Patient is accessible and compliant for follow-up. - Prostate cancer diagnosis cannot be more than 3 years prior to baseline visit date. - No more than two prostate biopsies including the initial biopsy in which cancer was diagnosed. - If cancer diagnosis is more than one year before enrollment, there must be two prostate biopsies including the initial biopsy in which cancer was diagnosed and a subsequent biopsy. The subsequent biopsy may occur on the same day as the baseline visit. - Biopsies must have at least 10 cores. Who Should NOT Join This Trial: - Unwillingness or inability to undergo serial prostate biopsy. - History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for \> 5 years. Always talk to your doctor about whether this trial is right for you.